Well, the incongruence remains all too stark and obvious to me.
And I rather suspect, I won't be the only one.
By the way, who are those associates you mentioned that think this trial has gone on long enough? What are their credentials?
Are they just common or garden impatient investors wishing to realize a quick profit by predicting the time of topline announcement, or do any of them have real expertise in the areas of biotech, immunotherapy response kinetics, statistical analysis, or regulatory affairs?